<DOC>
	<DOC>NCT02573272</DOC>
	<brief_summary>Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.</brief_summary>
	<brief_title>Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors</brief_title>
	<detailed_description />
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Patients over 18 years patients definitively diagnosed Focal Epilepsy based on clinical criteria and additional tests. patients with stable and identifiable antiepileptic treatment during the last two years. patients according to the investigator are able to provide clinical data necessary for the development of the study Patients who signed informed consent Patients who, according to their evolution and demands of clinical practice, their previous treatment has to be changed for this reason breach inclusion criteria and / or attachment to one of the study groups.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>